胰臟癌诊断市场－全球产业规模、份额、趋势、机会和预测（按检测类型、癌症类型、最终用户、地区和竞争细分，2020-2030 年）

2024 年全球胰臟癌诊断市场价值为 28.7 亿美元，预计到 2030 年将达到 43.2 亿美元，预测期内的复合年增长率为 7.05%。由于胰臟癌发病率不断上升、对微创诊断技术的需求增加以及研发投入不断增加，市场发展势头强劲。由于胰腺癌进展隐匿且往往在晚期才被发现，因此它仍然是最致命的癌症之一。随着人们对早期筛检及其对存活结果影响的认识不断提高，对有效诊断工具的需求显着增加。此外，全球人口老化（尤其是 60 岁及以上人口）导致胰臟癌发病率上升，进一步推动了对早期检测技术和诊断进步的需求。

关键市场驱动因素

胰臟癌发生率上升

主要市场挑战

由于症状不典型而导致诊断延迟

主要市场趋势

重视早期发现与个人化医疗

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球胰臟癌诊断市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依测试类型（诊断影像检查、切片、血液检查、肝功能检查、其他）
  • 依癌症类型（外分泌癌症、腺癌、鳞状细胞癌、胶体癌、其他）
  • 按最终使用者（医院和诊所、诊断中心、其他）
  • 按地区
  • 按公司分类（2024）
• 产品图
  • 按测试类型
  • 按癌症类型
  • 按最终用户
  • 按地区

第六章：北美胰臟癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲胰臟癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太胰臟癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲胰臟癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东与非洲胰臟癌诊断市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球胰臟癌诊断市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

The Global Pancreatic Cancer Diagnostics Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.32 billion by 2030, registering a CAGR of 7.05% during the forecast period. The market is gaining momentum due to the growing incidence of pancreatic cancer, increased demand for minimally invasive diagnostic techniques, and rising investments in R&D. Pancreatic cancer remains one of the deadliest forms of cancer due to its silent progression and late-stage detection. As awareness grows around early screening and its impact on survival outcomes, the demand for effective diagnostic tools has increased significantly. Moreover, the aging global population-particularly those aged 60 and above-has contributed to a higher incidence of pancreatic cancer, further driving demand for early detection technologies and diagnostic advancements.

Key Market Drivers

Rising Incidence of Pancreatic Cancer

The rising global incidence of pancreatic cancer serves as a major catalyst for the growth of the pancreatic cancer diagnostics market. According to the American Cancer Society, around 66,440 individuals in the U.S. are expected to be diagnosed with pancreatic cancer in 2024, with an estimated 51,750 fatalities. This high mortality rate emphasizes the urgency for improved diagnostic solutions. Globally, the increasing burden of pancreatic cancer is influenced by aging populations, evolving lifestyles, and environmental risk factors. As the disease is often diagnosed at a late stage due to its aggressive progression, healthcare systems are focusing more on developing advanced diagnostics that enable early and accurate detection.

Key Market Challenges

Late Diagnosis Due to Non-Specific Symptoms

One of the primary obstacles in pancreatic cancer diagnostics is the difficulty in early detection due to vague and non-specific symptoms such as abdominal discomfort, unexplained weight loss, and jaundice. These symptoms often resemble those of less severe conditions, causing significant delays in diagnosis. As a result, patients are frequently diagnosed at advanced stages when treatment options are limited. Although novel tools like the PAC-MANN blood test-showing 85% accuracy when used alongside CA 19-9-present promising results, broader implementation remains hindered by the need for further clinical validation and regulatory approvals.

Key Market Trends

Emphasis on Early Detection and Personalized Medicine

A prominent trend shaping the pancreatic cancer diagnostics market is the increasing emphasis on early detection and the integration of personalized medicine. Advances in diagnostic technologies, including experimental blood tests with up to 97% accuracy for stage 1 and 2 cancers, highlight the potential for improving outcomes through early diagnosis. Simultaneously, personalized approaches based on genetic profiling are gaining traction. Genomic testing enables identification of actionable mutations, allowing clinicians to customize treatment plans. Recent studies indicate that nearly one-third of patients with advanced pancreatic cancer had their treatments modified based on such insights, reinforcing the growing importance of precision diagnostics.

Key Market Players

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type:

• Diagnostic Imaging Tests
• Biopsy
• Blood Tests
• Liver Function Tests
• Others

Pancreatic Cancer Diagnostics Market, By Cancer Type:

• Exocrine
• Adenocarcinoma
• Squamous Cell Carcinoma
• Colloid Carcinoma
• Others

Pancreatic Cancer Diagnostics Market, By End User:

• Hospitals & Clinics
• Diagnostic Centers
• Others

Pancreatic Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Diagnostic Imaging Tests, Biopsy, Blood Tests, Liver Function Tests, Others)
    • 5.2.1.1. By Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
  • 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Map
  • 5.3.1. By Test Type
  • 5.3.2. By Cancer Type
  • 5.3.3. By End User
  • 5.3.4. By Region

6. North America Pancreatic Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Cancer Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Cancer Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Pancreatic Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Cancer Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End User

9. South America Pancreatic Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Cancer Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pancreatic Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Cancer Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Siemens Healthineers AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Myriad Genetics, Inc.
• 15.3. Pfizer, Inc
• 15.4. Novartis AG
• 15.5. AstraZeneca plc
• 15.6. Immunovia AB
• 15.7. Laboratory Corporation of America Holdings
• 15.8. Abbott Laboratories
• 15.9. Agilent Technologies, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer